318 related articles for article (PubMed ID: 34712204)
1. Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors.
Wen S; Li J; Yang J; Li B; Li N; Zhan X
Front Endocrinol (Lausanne); 2021; 12():753606. PubMed ID: 34712204
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation-Mediated Molecular Pathway Changes in Human Pituitary Neuroendocrine Tumors Identified by Quantitative Phosphoproteomics.
Li J; Wen S; Li B; Li N; Zhan X
Cells; 2021 Aug; 10(9):. PubMed ID: 34571875
[TBL] [Abstract][Full Text] [Related]
3. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
[TBL] [Abstract][Full Text] [Related]
4. Identification of biomarkers associated with the invasion of nonfunctional pituitary neuroendocrine tumors based on the immune microenvironment.
Wu J; Guo J; Fang Q; Liu Y; Li C; Xie W; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1131693. PubMed ID: 37522128
[TBL] [Abstract][Full Text] [Related]
5. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic analysis identifies a tumor subtype mRNA classifier for invasive non-functioning pituitary neuroendocrine tumor diagnostics.
Bao X; Wang G; Yu S; Sun J; He L; Zhao H; Ma Y; Wang F; Wang X; Wang R; Yu J
Theranostics; 2021; 11(1):132-146. PubMed ID: 33391466
[No Abstract] [Full Text] [Related]
7. Identification of cholesterol metabolism-related subtypes in nonfunctioning pituitary neuroendocrine tumors and analysis of immune infiltration.
Feng T; Hou P; Mu S; Fang Y; Li X; Li Z; Wang D; Chen L; Lu L; Lin K; Wang S
Lipids Health Dis; 2023 Aug; 22(1):127. PubMed ID: 37563740
[TBL] [Abstract][Full Text] [Related]
8. SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth
Wang X; Fang Y; Zhou Y; Guo X; Xu K; Li C; Zhang J; Hong Y
Front Endocrinol (Lausanne); 2020; 11():566761. PubMed ID: 33362712
[TBL] [Abstract][Full Text] [Related]
9. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.
Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
Acta Neuropathol Commun; 2019 Nov; 7(1):172. PubMed ID: 31703742
[TBL] [Abstract][Full Text] [Related]
10. Differential Expression of HMGA1 and HMGA2 in pituitary neuroendocrine tumors.
Portovedo S; Gaido N; de Almeida Nunes B; Nascimento AG; Rocha A; Magalhães M; Nascimento GC; Pires de Carvalho D; Soares P; Takiya C; Faria MDS; Miranda-Alves L
Mol Cell Endocrinol; 2019 Jun; 490():80-87. PubMed ID: 30999005
[TBL] [Abstract][Full Text] [Related]
11. DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors.
García-Martínez A; Sottile J; Sánchez-Tejada L; Fajardo C; Cámara R; Lamas C; Barberá VM; Picó A
J Clin Endocrinol Metab; 2019 Apr; 104(4):1272-1282. PubMed ID: 30423170
[TBL] [Abstract][Full Text] [Related]
12. Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis.
Tebani A; Jotanovic J; Hekmati N; Sivertsson Å; Gudjonsson O; Edén Engström B; Wikström J; Uhlèn M; Casar-Borota O; Pontén F
Acta Neuropathol Commun; 2021 Nov; 9(1):181. PubMed ID: 34758873
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of β-catenin at Serine552 correlates with invasion and recurrence of non-functioning pituitary neuroendocrine tumours.
Rai A; Yelamanchi SD; Radotra BD; Gupta SK; Mukherjee KK; Tripathi M; Chhabra R; Ahuja CK; Kumar N; Pandey A; Korbonits M; Dutta P; Gaston-Massuet C
Acta Neuropathol Commun; 2022 Sep; 10(1):138. PubMed ID: 36114575
[TBL] [Abstract][Full Text] [Related]
14. Aggressive nonfunctioning pituitary neuroendocrine tumors.
Portovedo S; Neto LV; Soares P; Carvalho DP; Takiya CM; Miranda-Alves L
Brain Tumor Pathol; 2022 Oct; 39(4):183-199. PubMed ID: 35725837
[TBL] [Abstract][Full Text] [Related]
15. Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
Herrgott GA; Asmaro KP; Wells M; Sabedot TS; Malta TM; Mosella MS; Nelson K; Scarpace L; Barnholtz-Sloan JS; Sloan AE; Selman WR; deCarvalho AC; Poisson LM; Mukherjee A; Robin AM; Lee IY; Snyder J; Walbert T; Rosenblum M; Mikkelsen T; Bhan A; Craig J; Kalkanis S; Rock J; Noushmehr H; Castro AV
Neuro Oncol; 2022 Jul; 24(7):1126-1139. PubMed ID: 35212383
[TBL] [Abstract][Full Text] [Related]
16. Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.
Spada A; Mantovani G; Lania AG; Treppiedi D; Mangili F; Catalano R; Carosi G; Sala E; Peverelli E
Neuroendocrinology; 2022; 112(1):15-33. PubMed ID: 33524974
[TBL] [Abstract][Full Text] [Related]
17. Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on AKT Phosphorylation and Cell Proliferation in Pituitary Tumors.
Mangili F; Giardino E; Treppiedi D; Barbieri AM; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Mantovani G; Peverelli E
Neuroendocrinology; 2021; 111(6):568-579. PubMed ID: 32512568
[TBL] [Abstract][Full Text] [Related]
18. Identification of the enhancer RNAs related to tumorgenesis of pituitary neuroendocrine tumors.
Wang L; Wei C; Wang Y; Huang N; Zhang T; Dai Y; Xue L; Lin S; Wu ZB
Front Endocrinol (Lausanne); 2023; 14():1149997. PubMed ID: 37534217
[TBL] [Abstract][Full Text] [Related]
19. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.
Mangili F; Esposito E; Treppiedi D; Catalano R; Marra G; Di Muro G; Barbieri AM; Locatelli M; Lania AG; Mangone A; Spada A; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2022; 13():867822. PubMed ID: 35721701
[TBL] [Abstract][Full Text] [Related]
20. Lysine Methyltransferase 5A Promotes the Progression of Growth Hormone Pituitary Neuroendocrine Tumors through the Wnt/β-Catenin Signaling Pathway.
Li J; Song H; Chen T; Zhang S; Zhang C; Ma C; Zhang L; Wang T; Qian Y; Deng X
Neuroendocrinology; 2024; 114(6):589-601. PubMed ID: 38565081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]